May 17 2010
BaroFold, Inc. today announced that it has entered into an agreement to exclusively license its PreEMT™ Technology to Nuron Biotech for the development of BaroFeron™ and follow-on interferon beta products. BaroFeron is a proprietary recombinant human interferon beta being developed for the treatment of multiple sclerosis. Specific terms of the agreement are not disclosed.
“BaroFeron's proprietary and improved structure may result in reduced immune responses compared to other interferon beta products. The application of PreEMT in developing BaroFeron and the promising Phase 1 clinical data serve as positive validation for PreEMT.”
"BaroFeron is an optimized, aggregate-free version of interferon beta-1b created by applying BaroFold's PreEMT high pressure protein disaggregation and refolding technology," said Matthew Brewer, President and CEO of BaroFold. "BaroFeron's proprietary and improved structure may result in reduced immune responses compared to other interferon beta products. The application of PreEMT in developing BaroFeron and the promising Phase 1 clinical data serve as positive validation for PreEMT."
"Further, this transaction demonstrates BaroFold's strategic business focus on leveraging PreEMT as the technology of choice to support its industry partners' efforts to create novel protein therapeutics, manufacture follow-on biologics and conduct life-cycle management of protein therapeutics," continued Brewer.
"BaroFeron exemplifies Nuron's focus on developing and commercializing biotherapeutics with enhanced product profiles," said Shankar Musunuri, Ph.D., MBA, CEO of Nuron. "We are currently developing the clinical and regulatory strategy for advanced clinical trials of BaroFeron and look forward to advancing this exciting candidate."
Novel SARS-CoV-2 mutations found in floodwaters near homeless communities